Ascendis Pharma A/S (NASDAQ:ASND) Receives $204.64 Average Target Price from Analysts

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $204.64.

Several analysts have recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Finally, Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. lifted its stake in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after buying an additional 114,167 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Ascendis Pharma A/S by 0.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after buying an additional 39,309 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the last quarter. Finally, Capital International Investors raised its stake in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after acquiring an additional 753,859 shares in the last quarter.

Remove Ads

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded down $3.26 during trading on Tuesday, hitting $154.68. 289,067 shares of the company were exchanged, compared to its average volume of 465,825. The company has a fifty day moving average price of $144.16 and a 200-day moving average price of $137.01. The firm has a market capitalization of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.